Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid(®)) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty(®))

A recombinant SARS-CoV-2 spike protein vaccine (NVX-CoV2373) has been licensed and has a lesser incidence of adverse events. To know the immunological mechanisms of adverse events, the production of cytokines and chemokines was investigated in mice inoculated with NVX-CoV2373. Serum IL-6 was detecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Tetsuo, Ito, Takashi, Ishiyama, Ryoka, Katayama, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675389/
https://www.ncbi.nlm.nih.gov/pubmed/38006009
http://dx.doi.org/10.3390/vaccines11111677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675389/
https://www.ncbi.nlm.nih.gov/pubmed/38006009
http://dx.doi.org/10.3390/vaccines11111677

Ejemplares similares